Aclaris Therapeutics (NASDAQ:ACRS) Lowered to Sell Rating by StockNews.com

Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. According to data from MarketBeat, Aclaris Therapeutics presently has an average rating of “Hold” and an average price target of $9.00.

Aclaris Therapeutics Price Performance

Shares of Aclaris Therapeutics stock traded up $0.19 during trading on Thursday, hitting $2.45. 1,005,888 shares of the company’s stock traded hands, compared to its average volume of 998,016. Aclaris Therapeutics has a 1 year low of $0.59 and a 1 year high of $5.61. The stock has a market capitalization of $174.80 million, a P/E ratio of -2.99 and a beta of 0.10. The business has a 50-day simple moving average of $1.32 and a 200-day simple moving average of $1.24.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 183.28% and a negative return on equity of 53.18%. The firm had revenue of $4.35 million during the quarter, compared to the consensus estimate of $8.31 million. On average, equities analysts predict that Aclaris Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Aclaris Therapeutics in the first quarter worth about $39,000. SG Americas Securities LLC raised its stake in shares of Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after buying an additional 13,461 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Aclaris Therapeutics by 5,265.1% in the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after buying an additional 61,602 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Aclaris Therapeutics in the second quarter worth about $119,000. Finally, Assenagon Asset Management S.A. bought a new position in shares of Aclaris Therapeutics in the third quarter worth about $214,000. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.